Investors & Media

Press Releases



All Releases
View Summary TG Therapeutics, Inc. Recaps Clinical Data Presentations at the Upcoming 7th Joint ECTRIMS - ACTRIMS Meeting
Oct 16, 2017
PDF 286.8 KB Add to Briefcase
View Summary TG Therapeutics Announces Completion of Full Enrollment in the UNITY-CLL Phase 3 Trial
Oct 16, 2017
PDF 283.0 KB Add to Briefcase
View Summary TG Therapeutics Provides Update on FDA Meeting for GENUINE Phase 3 Trial
Oct 16, 2017
PDF 281.8 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Advancement of its Anti-PD-L1 Monoclonal Antibody into Clinical Development
Oct 5, 2017
PDF 281.4 KB Add to Briefcase
View Summary TG Therapeutics Announces TGR-1202 (umbralisib) Selected For Grant from the National Multiple Sclerosis Society to Support the Development of TGR-1202 as an Oral B-cell Targeted Treatment Option in Progressive Multiple Sclerosis (PMS)
Sep 29, 2017
PDF 283.1 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Present at Upcoming Investor Conferences
Sep 21, 2017
PDF 278.1 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces the Phase 3 ULTIMATE Trials Evaluating TG-1101 in Patients with Multiple Sclerosis Are Now Open for Enrollment
Sep 15, 2017
PDF 281.9 KB Add to Briefcase
View Summary TG Therapeutics Announces Completion of Target Enrollment in the UNITY-CLL Phase 3 Trial
Sep 5, 2017
PDF 282.8 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 7th Joint ECTRIMS - ACTRIMS Meeting
Sep 1, 2017
PDF 284.8 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Successful Outcome from the First Pre-Planned Interim Analysis by Independent DSMB of the DLBCL Cohort in the UNITY-NHL Phase 2b Trial
Aug 10, 2017
PDF 281.9 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2017 Financial Results
Aug 9, 2017
PDF 293.6 KB Add to Briefcase
View Summary TG Therapeutics, Inc. to Host Conference Call on Second Quarter 2017 Financial Results and Business Update
Aug 7, 2017
PDF 278.8 KB Add to Briefcase
View Summary TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement with the FDA for a Phase 3 Program of TG-1101 (ublituximab) for Patients with Multiple Sclerosis (MS)
Aug 1, 2017
PDF 283.2 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Recaps Data from Triple Combination Therapy Trials at the 22nd European Hematology Association Annual Congress
Jun 26, 2017
PDF 325.7 KB Add to Briefcase
View Summary TG Therapeutics Recaps Preliminary Results from Ongoing Phase 2 Study of TG-1101 (ublituximab) in Patients with Multiple Sclerosis at the 3rd Congress of the European Academy of Neurology
Jun 26, 2017
PDF 284.3 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Recaps Positive Data from the Phase 3 GENUINE Trial and Data from the Triple Combination of TG-1101, TGR-1202, and Ibrutinib at the 14th International Conference on Malignant Lymphoma
Jun 16, 2017
PDF 331.0 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Follow-Up Data from the Triple Combination of TG-1101, TGR-1202, and Bendamustine in Patients with DLBCL and FL at the 14th International Conference on Malignant Lymphoma
Jun 15, 2017
PDF 285.7 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Follow-Up Data for Combination of TGR-1202 (umbralisib) plus Ibrutinib in Patients with Relapsed or Refractory CLL and MCL at the 14th International Conference on Malignant Lymphoma
Jun 14, 2017
PDF 285.6 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Recaps Schedule of Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma & the 22nd European Hematology Association Annual Congress
Jun 13, 2017
PDF 286.4 KB Add to Briefcase
View Summary TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 14th International Conference on Malignant Lymphoma
Jun 8, 2017
PDF 284.4 KB Add to Briefcase
Showing 1-20 of 208 Page: 1 2 3 4 5 ... 11  Next 20
Add to Briefcase = add release to Briefcase